Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Department of Cardiology, The First Affiliated Hospital of Chongqing Medical University, Chongqing, China.
Mayo Clin Proc. 2019 Sep;94(9):1695-1706. doi: 10.1016/j.mayocp.2019.07.005. Epub 2019 Aug 8.
To assess the efficacy and safety of catheter-based renal denervation (RDN) for the treatment of uncontrolled hypertension by conducting a systematic review and a meta-analysis.
The Medline, Cochrane Library, and Embase databases were searched for clinical studies between January 1, 2009, and July 16, 2018. Studies that evaluated the effect of RDN on uncontrolled hypertension were identified. The primary endpoints were changes in 24-hour ambulatory systolic blood pressure (BP) and office systolic BP. The secondary endpoints included changes in 24-hour ambulatory diastolic BP, office diastolic BP, and major adverse events.
After a literature search and detailed evaluation, 12 randomized controlled trials with a total of 1539 individuals were included in the quantitative analysis. Pooled analyses indicated that RDN was associated with a significantly greater reduction of 24-hour systolic BP (mean difference [MD], -4.02 mm Hg; 95% CI, -5.49 to -2.56; P<.001) and office systolic BP (MD, -8.93 mm Hg; 95% CI, -14.03 to -3.83; P<.001) than controls. Similarly, RDN significantly reduced 24-hour diastolic BP (MD, -2.05 mm Hg; 95% CI, -3.05 to -1.05; P<.001) and office diastolic BP (MD, -4.49 mm Hg; 95% CI, -6.46 to -2.52; P<.001). RDN was not associated with an increased risk of major adverse events (relative risk, 1.06; 95% CI, 0.72 to 1.57; P=.76).
Catheter-based RDN was associated with a significant BP-lowering benefit without increasing major adverse events.
通过系统评价和荟萃分析评估基于导管的肾脏去神经术(RDN)治疗未控制高血压的疗效和安全性。
检索了 2009 年 1 月 1 日至 2018 年 7 月 16 日期间的 Medline、Cochrane 图书馆和 Embase 数据库中的临床研究。确定了评估 RDN 对未控制高血压影响的研究。主要终点是 24 小时动态收缩压(BP)和诊室收缩压的变化。次要终点包括 24 小时动态舒张压、诊室舒张压和主要不良事件的变化。
经过文献检索和详细评估,共纳入了 12 项随机对照试验,共有 1539 人进行了定量分析。汇总分析表明,RDN 与 24 小时收缩压(平均差值 [MD],-4.02mmHg;95%CI,-5.49 至-2.56;P<.001)和诊室收缩压(MD,-8.93mmHg;95%CI,-14.03 至-3.83;P<.001)的显著降低相关。同样,RDN 也显著降低了 24 小时舒张压(MD,-2.05mmHg;95%CI,-3.05 至-1.05;P<.001)和诊室舒张压(MD,-4.49mmHg;95%CI,-6.46 至-2.52;P<.001)。RDN 与主要不良事件风险增加无关(相对风险,1.06;95%CI,0.72 至 1.57;P=.76)。
基于导管的 RDN 可显著降低血压,且不会增加主要不良事件。